2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
37
Carcinoma, Non-Small-Cell Lung
24
Melanoma
19
Squamous Cell Carcinoma of Head and Neck
18
Colorectal Neoplasms
16
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Lung Neoplasms
10
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Carcinoma, Renal Cell
9
Neoplasms
8
Cholangiocarcinoma
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Mesothelioma, Malignant
5
Fallopian Tube Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Mesothelioma
3
Kidney Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Therapeutics
1
Immunotherapy
1
Bumetanide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unresectable Hepatocellular Carcinoma
×
tremelimumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled